Vertex Pharmaceuticals Inc
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For.
Profit margin of 32.9% — that's well above average.
Current Price
$446.78
+0.64%GoodMoat Value
$284.70
36.3% overvaluedVertex Pharmaceuticals Inc (VRTX) Stock Chart
VRTX Interactive Stock Chart
Interactive stock chart for Vertex Pharmaceuticals Inc (VRTX) with candlestick and line chart views. Analyze price action across multiple timeframes: 5 days, 1 week, 1 month, 3 months, 6 months, 1 year, 5 years, and full history.
Current price: $446.78. 52-week high: $509.50. 52-week low: $366.54. 50-day moving average: $465.29. 200-day moving average: $438.23.
Technical analysis indicators include Volume, SMA 20, SMA 50, SMA 200, EMA 20, and RSI. Toggle between candlestick and line chart styles. Overlay multiple moving averages to identify support and resistance levels, trend direction, and momentum signals for VRTX. Use the chart alongside GoodMoat's fundamental analysis tools for a complete picture of Vertex Pharmaceuticals Inc's investment potential.